PT  - JOURNAL ARTICLE
AU  - Harrison J. McNabb
AU  - Qian Zhang
AU  - Benita Sjögren
TI  - Emerging Roles for Regulator of G Protein Signaling 2 in (Patho)physiology
AID  - 10.1124/molpharm.120.000111
DP  - 2020 Dec 01
TA  - Molecular Pharmacology
PG  - 751--760
VI  - 98
IP  - 6
4099  - http://molpharm.aspetjournals.org/content/98/6/751.short
4100  - http://molpharm.aspetjournals.org/content/98/6/751.full
SO  - Mol Pharmacol2020 Dec 01; 98
AB  - Since their discovery in the mid-1990s, regulator of G protein signaling (RGS) proteins have emerged as key regulators of signaling through G protein–coupled receptors. Among the over 20 known RGS proteins, RGS2 has received increasing interest as a potential therapeutic drug target with broad clinical implications. RGS2 is a member of the R4 subfamily of RGS proteins and is unique in that it is selective for Gαq. Despite only having an RGS domain, responsible for the canonical GTPase activating protein activity, RGS2 can regulate additional processes, such as protein synthesis and adenylate cyclase activity, through protein-protein interactions. Here we provide an update of the current knowledge of RGS2 function as it relates to molecular mechanisms of regulation as well as its potential role in regulating a number of physiologic systems and pathologies, including cardiovascular disease and central nervous system disorders, as well as various forms of cancer.SIGNIFICANCE STATEMENT Regulator of G protein signaling (RGS) proteins represent an exciting class of novel drug targets. RGS2, in particular, could have broad clinical importance. As more details are emerging on the regulation of RGS2 in various physiological systems, the potential utility of this small protein in therapeutic development is increasing.